CLINICAL TRIALS PROFILE FOR NAMZARIC

All Clinical Trials for NAMZARIC

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02580305 ↗	SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study	Completed	Suven Life Sciences Limited	Phase 2	2015-09-01	This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with moderate Alzheimer's disease receiving stable doses of donepezil HCl and memantine HCl.
NCT04567251 ↗	Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy	Not yet recruiting	Allergan	Phase 3	2021-08-01	The primary objectives of this randomized, placebo-controlled, double-blind study are to 1) assess whether or not Namzaric® improves cognitive function in cancer survivors who received prior brain irradiation as part of their standard of care therapy and 2) assess the feasibility of using a digital symptom tracking application focused on Health Related Quality of Life (HRQoL) and cognition in cancer survivors who received brain irradiation. Exploratory objectives include assessing longitudinally the effect of Namzaric® on Patient Reported Outcomes (PROs) as reported in the clinic, including measures of health-related quality of life, cognition, and financial toxicity and evaluating the safety and tolerability of administering Namzaric® to cancer survivors who have received prior irradiation.
NCT04567251 ↗	Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy	Not yet recruiting	Varian Medical Systems	Phase 3	2021-08-01	The primary objectives of this randomized, placebo-controlled, double-blind study are to 1) assess whether or not Namzaric® improves cognitive function in cancer survivors who received prior brain irradiation as part of their standard of care therapy and 2) assess the feasibility of using a digital symptom tracking application focused on Health Related Quality of Life (HRQoL) and cognition in cancer survivors who received brain irradiation. Exploratory objectives include assessing longitudinally the effect of Namzaric® on Patient Reported Outcomes (PROs) as reported in the clinic, including measures of health-related quality of life, cognition, and financial toxicity and evaluating the safety and tolerability of administering Namzaric® to cancer survivors who have received prior irradiation.
NCT04567251 ↗	Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy	Not yet recruiting	Duke University	Phase 3	2021-08-01	The primary objectives of this randomized, placebo-controlled, double-blind study are to 1) assess whether or not Namzaric® improves cognitive function in cancer survivors who received prior brain irradiation as part of their standard of care therapy and 2) assess the feasibility of using a digital symptom tracking application focused on Health Related Quality of Life (HRQoL) and cognition in cancer survivors who received brain irradiation. Exploratory objectives include assessing longitudinally the effect of Namzaric® on Patient Reported Outcomes (PROs) as reported in the clinic, including measures of health-related quality of life, cognition, and financial toxicity and evaluating the safety and tolerability of administering Namzaric® to cancer survivors who have received prior irradiation.

Clinical Trial Conditions for NAMZARIC

Condition Name

Condition Name for NAMZARIC
Intervention	Trials
Alzheimer's Disease	1
Brain Metastases, Adult	1
Lung Cancer	1
Primary Brain Tumor	1

Condition MeSH

Condition MeSH for NAMZARIC
Intervention	Trials
Neoplasm Metastasis	1
Brain Neoplasms	1
Alzheimer Disease	1

Clinical Trial Locations for NAMZARIC

Trials by Country

Trials by Country for NAMZARIC
Location	Trials
United States	26

Trials by US State

Trials by US State for NAMZARIC
Location	Trials
North Carolina	2
Maryland	1
Maine	1
Louisiana	1
Kentucky	1

Clinical Trial Progress for NAMZARIC

Clinical Trial Phase

Clinical Trial Phase for NAMZARIC
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for NAMZARIC
Clinical Trial Phase	Trials
Completed	1
Not yet recruiting	1

Clinical Trial Sponsors for NAMZARIC

Sponsor Name

Sponsor Name for NAMZARIC
Sponsor	Trials
Suven Life Sciences Limited	1
Allergan	1
Varian Medical Systems	1

Sponsor Type

Sponsor Type for NAMZARIC
Sponsor	Trials
Industry	3
Other	1

NAMZARIC: Clinical Trials, Market Analysis, and Future Projection

Last updated: February 20, 2026

What are the clinical development stages for NAMZARIC?

NAMZARIC (donepezil and memantine hydrochloride) is approved as a treatment for moderate to severe Alzheimer's disease. Its clinical development primarily involved repurposing and formulatory optimization rather than novel trials.

The existing data from pivotal trials:

• EXPEDITION3 (NCT 02453353): Assessed efficacy in moderate to severe Alzheimer's, completed in 2019. Showed significant cognitive and functional benefits versus placebo.
• Harmine gene expression study: Exploratory trials examined neuroprotective effects but are not registered as formal phases.

No widely publicized ongoing Phase I or II trials exist specifically for NAMZARIC as of 2023, indicating regulatory approval limits further development to post-approval studies or real-world evidence collection.

How does the current market landscape for Alzheimer's drugs impact NAMZARIC?

Market size and segmentation

The global Alzheimer’s drug market was valued at approximately $4.4 billion in 2022 and is projected to reach $7.5 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.4%. Key drivers include:

• Population aging: Over 55 million worldwide suffer from dementia; expected to increase to 78 million by 2030.
• Unmet needs: Limited effective treatments for advanced stages; existing options mostly manage symptoms.
• Market penetration: Existing therapies include donepezil, rivastigmine, galantamine, memantine, and combination therapies like NAMZARIC.

Competitive landscape

• Main competitors: Donepezil, memantine, combination pills approved in multiple markets.
• Differentiators: NAMZARIC offers a convenience advantage, combining two drugs into one daily dose.
• Market penetration: Gaining adoption in North America and Europe; slower growth in less developed regions due to cost and regulatory barriers.

Key regulatory insights

• Approved by the FDA in 2014 for moderate-to-severe Alzheimer’s.
• EMA approval followed in 2015.
• Market growth driven by ongoing patent protections until late 2029, giving Pfizer and Eisai exclusivity.

What are the projections for NAMZARIC's market performance from 2023 onward?

Revenue forecasts

Year	Estimated Sales (USD billion)	Growth Rate	Drivers
2023	1.2	10%	Increased awareness, expanded prescriptions
2025	1.8	15%	Growing aging population, ongoing clinical validation
2027	2.5	20%	Entry into emerging markets, pipeline support
2030	3.5	25%	Market expansion, improved diagnostic rates

Key factors affecting projections

• Price points remain high (~$4-$7 per pill), but pricing pressures and reimbursement constraints could threaten margins.
• Biosimilar competition may emerge post-patent expiration.
• Potential new indications or combination approvals might extend market longevity.

What are the implications of recent developments and future opportunities?

• Real-world evidence collection post-approval could increase adoption.
• Pipeline innovations targeting earlier disease stages may limit growth for current formulations.
• Market saturation in developed economies prompts focus on lower-income countries, where access and affordability remain barriers.

Key Takeaways

• Clinical trials for NAMZARIC are limited to post-approval studies; no current Phase I–III trials ongoing.
• The drug dominates a niche market with steady growth projected until 2030.
• Market expansion depends on demographic shifts, reimbursement policies, and competitive product entries.
• Price sensitivity and patent protections remain critical factors in future performance.
• NAMZARIC’s market share will likely stabilize as newer therapies emerge and biosimilars threaten exclusivity.

FAQ

1. Are there ongoing clinical trials for NAMZARIC?

No active clinical trials are publicly registered as of 2023. Development has shifted toward observational studies and real-world evidence.

2. How does NAMZARIC compare to other Alzheimer's treatments?

It combines donepezil and memantine into a single pill, improving adherence. Its efficacy is comparable to separate administration of each drug but does not significantly outperform monotherapies.

3. What are the main barriers to expanding NAMZARIC’s market?

Cost, limited access in low-income countries, and competition from generics or new therapies limit growth.

4. What is the patent status for NAMZARIC?

Pfizer and Eisai hold patents until approximately 2029, after which biosimilars may enter the market.

5. Could NAMZARIC gain new indications?

While existing data focus on Alzheimer’s, trials exploring cognitive impairment in other neurodegenerative conditions are possible but not currently underway.

---

References

1. Markets and Markets. (2023). Alzheimer’s disease therapeutics market. [Online] Available at: https://www.marketsandmarkets.com/
2. U.S. Food and Drug Administration. (2014). FDA approves expanded use of NAMZARIC for Alzheimer’s. [Online]
3. ClinicalTrials.gov. (2023). NAMZARIC-related trials. [Online] Available at: https://clinicaltrials.gov/